Since the introduction by Barraquer of enzymatic zonulolysis using α-chymotrypsin to produce lysis of the zonular fibers and facilitate intracapsular removal of cataract, many reports from all parts of the world have appeared in the literature describing various authors' experiences with the new method. Invariably they extol the enzyme for its fibrinolytic and proteolytic properties which make removal of the lens easier. At least one prominent ophthalmic surgeon is so enthusiastic he uses α-chymotrypsin in all his cataract operations.
Many of the reports mention, without going into details, unfavorable effects such as interference with wound healing and abnormally high incidence of corneal edema, but apparently such unfavorable incidents have not occurred with sufficient frequency or severity to dampen the zeal of the authors for zonulolysis. Very few, among whom are Konstas and Chachamidis,1 give actual figures for complications (delayed reformation of anterior chamber: 38% with α-chymotrypsin, 13% without α-chymotrypsin).
TOWNES CD. Unfavorable Effects of Alpha-Chymotrypsin in Cataract Surgery. AMA Arch Ophthalmol. 1960;64(1):108–113. doi:10.1001/archopht.1960.01840010110010
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: